Title: Changes in life expectancy and life span equality during the COVID-19 epidemic

in Japan up to 2022.

Running title: Demographic impact of COVID-19 pandemic in Japan

Article type: Original Article

Authors:

Yuta Okada[a], Hiroshi Nishiura[a]

[a] Graduate School of Medicine, Kyoto University, Kyoto 6068503, Japan

Correspondence to: Hiroshi Nishiura

Address: Kyoto University, Yoshidakonoecho, Sakyoku, Kyoto city, Kyoto 6068503,

Japan

Tel: +81-75-753-4456; Fax: +81-75-753-4458

Email: nishiura.hiroshi.5r@kyoto-u.ac.jp

Abstract

Objectives: To evaluate the impact of COVID-19 on life expectancy in Japan through

demographic analyses.

Methods: We evaluated the relationship between life expectancy gap from 2020-21 and

2021-22 and indicators of COVID-19 epidemic size at prefectural level. We also

conducted age- and cause-specific decomposition of life expectancy change. Trends of

life span equality from 2000-22 were also evaluated at the national level.

Results: Prefectural analysis between 2021-22 life expectancy change and annual per-

population COVID-19 cases, person days in intensive care, reported COVID-19 deaths

did not reveal significant correlations, which was contrary to our analysis from 2020-21.

However, decomposition analysis revealed substantial life expectancy shortening

attributable to the over-35-year-old population, and large increases in death causes such

as cardiovascular or respiratory disorders along with COVID-19. Life span equality in

Japan for the total population declined in 2020 but increased in 2021 and 2022 despite

the shortening in life expectancy.

Conclusions: Discrepancy between life expectancy change and COVID-19 statistics in

2022 suggests the growing ascertainment bias of COVID-19. The increased contribution

of cardiovascular disorders to life expectancy shortening is an alarming sign for the

future. Life span equality in 2021 and 2022 is likely attributed to increased mortality

among the elderly.

Keywords: COVID-19; Life Expectancy; Life Tables; Cause of Death; Japan

Highlights

• Life expectancy change was not correlated with epidemic activity of COVID-19 in 2022

• Older people contributed to life expectancy shortening more than ever

• Cardiovascular disorders contributed substantially to life expectancy shortening

• Life span equality increased in 2021 and 2022 despite life expectancy shortening

1. Introduction

Since the start of the COVID-19 pandemic in Wuhan, China in November 2019,

evidence of the pandemic's impact on mortality has accumulated globally, with

substantial geographical heterogeneity. (1–6) Global studies suggest that from January

1st, 2020 to December 31st, 2021, excess deaths worldwide were in the range of 14.9–

15.9 million, with a large proportion attributed to India and the United States.(3,4)

Published studies suggest that the global life expectancy change was −1.6 years from

2019 to 2021, when many countries showed bounce-backs from the shortening in 2020.

However, other countries faced sustained shortening into 2021.(4–6)

It is now several years since the emergence of COVID-19, and the evaluation of the

mortality impact of the condition has become more difficult for several reasons. One

reason is changes in the official COVID-19 statistics, which are provided by public

health agencies around the world and reflect epidemic activity. These are now less

rigorous than in 2020, because most countries have gradually diminished their effort

either to control the spread of COVID-19 or to maintain a meticulous surveillance

system. Another reason is the change in the nature of deaths associated with COVID-19

since the introduction of vaccines against the disease in late 2020. The direct mortality

impact of COVID-19 has been alleviated by these vaccines, but a substantial proportion

of deaths are caused indirectly through complications such as cardiovascular disorders,

or by limited access to healthcare services when the healthcare capacity or ambulance

system were overwhelmed by the increased case load pressure of COVID-19. (5,7–15)

The ongoing emergence of SARS-CoV-2 variants with a high capability of immune

evasion and transmission may have worsened the health impact of COVID-19, but

understanding the true burden has remained a challenging task.(16,17)

Direct approaches to estimating the mortality impact of COVID-19 are therefore

challenging, including in Japan. There, the epidemic size of COVID-19 was greatest

upon the emergence of SARS-CoV-2 Omicron (B.1.1.529) lineage variants. In line with

other regions, Japan has been severely affected by COVID-19 in terms of excess

mortality and life expectancy shortening. (1,3–5,14,18–21) The updated estimates by

the National Institute of Population and Social Security Research suggest that life

expectancy at birth has shortened for two consecutive years, from 84.58 years in 2021

to 84.10 in 2022 for the total population. However, it is not clear whether the cause-

specific impact of this shortening has changed since 2021. It is also not clear how the

contribution of cardiovascular, respiratory, and neoplastic disorders in 2021 have

changed. (18) From a demographic perspective, the change in life span equality during

and since the COVID-19 pandemic is also interesting. One measure of life span equality,

or, evenness of life span, is the logarithm of the inverse of life table entropy. Global and

historical demographic analysis suggests that the trends in life expectancy at birth and

life span equality have been in line with each other. (22,23) However, this might not be

the case when the age–mortality structure changes drastically. For example, during the

COVID-19 epidemic in Japan, the mortality increase in 2021 contributed substantially

to shorter life expectancy. (18)

To examine the demographic impact of the COVID-19 epidemic in 2022 in Japan, we

investigated the relationship between reported COVID-19 burden at the prefectural level

and life expectancy. We also decomposed the year-on-year life expectancy change from

2019–22 by age groups and major causes of death, and evaluated the lifetime loss by

age and life span equality during the COVID-19 epidemic.

2. Material and methods

2.1. Epidemiological data

We used the data on deaths and exposure-to-risk populations available in the

Japanese Mortality Database (JMD), which was available for the whole of Japan and by

prefecture. (24) Death counts by cause of death and age group were obtained from the

vital statistics published by the Ministry of Health, Labour and Welfare of Japan.(25) In

line with a previous study, we categorized major causes of death using the International

Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-

10) into the top nine major cause categories (based on death counts by cause in 2022),

and aggregated the remainder into a single group, to give a total of ten groups.(18,25)

The epidemiological data for COVID-19 were retrieved from the open-access data

provided by the Ministry of Health, Labour and Welfare. (26)

2.2. Calculation of period life table and Arriaga decomposition

For subsequent use for age- and cause-specific decomposition of life expectancy

gaps, we re-calculated period life tables from 2000 to 2022 for the whole of Japan and

for all prefectures as described before. (18) For the age- and cause-specific

decomposition of life expectancy change, we used the Arriaga method for age- and

cause-specific decomposition of life expectancy change. (18,27,28)

2.3. Life expectancy change and COVID-19 statistics at the prefectural level

Three COVID-19 statistics at prefectural level were used for this analysis: (i)

annual number of COVID-19 cases, (ii) annual number of person-days in intensive care

because of COVID-19, and (iii) annual number of documented deaths due to COVID-19.

Using each of the COVID-19 indicators as an explanatory variable, we used linear

regression analysis to predict the year-on-year life expectancy change as the dependent

variable for 2020–21 and 2021–22.

2.4. Life span equality h

We used a measure of life span equality h, which was derived from life table

entropy $\bar{\bar{H}}$. (22,29–31) We used a 1×1 year life table provided by JMD to calculate $h(t)$

from 2000 to 2022 for total, male, and female populations, and evaluated the

relationship between $h(t)$ and life expectancy at birth, $e_0(t)$, for each of these

populations. (24) As in Aburto et al. (22), we also calculated $w(x, t)W_h(x, t)$, the

sensitivity of $h(t)$ to the rate of mortality improvement, and its threshold age a^H that

satisfies $W_h(a^H, t) = 0$ for $t = 2000, 2001, \ldots, 2022$. These results were compared

with year-on-year mortality improvement, i.e., $r(x, t) = \log(\mu(a, t)) - \log(\mu(a, t +$

$1))$, which is analogous to the rate of mortality improvement as described above.

2.5. Software

All analyses used R version 4.2.2.(32)

Results

The summary of life expectancies at birth in Japan for the total, male, and

female populations from 2019-2022 is shown in Supplementary Table 1. (Results based

on abridged life tables that we re-calculated for use in Arriaga decomposition, which are

almost identical to results provided by JMD) Life expectancy of the total population

decreased by 0.49 years, from 84.59 to 84.10 from 2021-22. Though the change in the

trend of life expectancy was already seen from 2020-21 by 0.15 years (from 84.74 to

84.59 years), the magnitude of shortening was greater in 2021-22. The shortening of life

expectancy at birth for male and female populations also grew greater from 2021-22,

estimated at 0.43 years (from 81.49 to 81.06 years) and 0.50 years (from 87.62 to 87.12

years), respectively.

Figure 1 shows life expectancy changes of the total population by prefecture in

2019–20, 2020-21, and 2021–2022. Following the drastic change from the overall

increasing trend in 2019-20 to the sharply decreasing trend in 2020-21, all except one

prefecture saw a decline in life expectancies from 2021-22. In 2022, the greatest

decrease in life expectancy was seen in Iwate (1.00 years), and the only prefecture that

enjoyed the increasing trend was Nagasaki (0.05 years). The prefecture level life

expectancy changes of male and female population were in mostly in line with that of

the total population. (For the details, see Supplementary Data)

Figure 2 presents the correlation between the reported COVID-19 burden and

life expectancy changes at the prefectural level. Combined with the linear regression

results as shown in Table 1, in 2021-22, the correlation between annual reported cases,

person-day under intensive care, and death due to COVID-19 was not evident. This was

contrary to the findings from 2020-21.

152    Figure 3 shows the results of Arriaga decomposition of life expectancy change

153 by age groups and major causes of death. (Aggregated summary by age groups or by

154 causes of death are available as Supplementary Figures 1 and 2) As for the contribution

155 by age, the negative contribution among the elderly population in 2020-21 was already

156 seen. However, the negative contribution of the elderly population is more eminent in

157 2021-22 than in 2020-21. Also, the range of elder age with negative contribution has

158 widened to younger quota in 2021-22 to as low as 30-34-year-olds.

159    As for contributions of major death causes by age groups which is also shown

160 in Figure 3, negative contribution by COVID-19 among the elderly population has

161 enlarged substantially in 2021-22, and the total contribution by all ages has grown from

162 -0.095 years in 2020-21 to -0.131 years in 2021-22. In addition to COVID-19, the

163 negative contribution of cardiovascular causes also grew much in 2021-22 especially

164 among age groups older than 50 years old. The total contribution of cardiovascular

165 death was -0.091 years in 2022 and has decreased consistently and substantially

166 compared with +0.073 years in 2020 and -0.003 years in 2021. The negative

167 contribution of "other" causes (the remainder of death causes that do not belong to the

168 top 9 major death cause categories) also increased substantially in 2021-22 among

169 elderly population older than 50 years old, with a total of -0.139 years across all age

groups. The decrease in the contribution of respiratory and neoplastic disorders as well

as that from other causes from 2020-21 to 2021-22 is also clearly observed. (See

Supplementary Data for detailed results). Results from the decomposition analysis for

the male and female populations were similar to that of the total population.

(Supplementary Data and Supplementary Figures 3 and 4)

The values of $h(t)$ as an indicator of life span equality for the total population

from 2000 to 2022 are shown in Figure 4. As shown in panel (A), h has mostly

increased monotonously up to 2019, with the exception of 2011 when an exceptional

number of casualties occurred due to the earthquake and tsunami that hit eastern Japan.

That increasing trend was halted in 2020 when the COVID-19 pandemic started, but has

resumed to increase since 2021. The values of $h(t)$ for female and male populations

also showed very similar patterns to those for the total population. (Supplementary

Figures 5 and 6) Panel (B) in Figure 4 shows the relationship between $h(t)$ and life

expectancy at birth from 2000 to 2022. A decrease in $h(t)$ was seen in 2020 for the first

time since 2011, and it was followed by an increase in 2021 and 2022 decreased despite

the shortening of life expectancy at birth.

To see how the overall dynamics of $h(t)$ from 2020 to 2022 can be explained

by mortality improvements by age for this period (in relation to a^H), we calculated the

curves of $w(x, t)W_h(x, t)$ across ages for 2021 and 2022, and also evaluated the year-

on-year mortality improvement $r(x, t)$ from 2020 to 2022 for the total population.

(Supplementary Figure 6) The curves of $w(x, t)W_h(x, t)$ for 2021 and 2022 were very

similar, although a slight shift toward the younger ages can be observed in the negative

part of the curve in the elderly population. As for $r(x, t)$, $r(x, 2020)$ above $x = a^H$ lied

in the positive range, whereas $r(x, 2021)$ and $r(x, 2022)$ mostly lied in the negative

range for the age range. For ages younger than $x = a^H$, the signs of $r(x, 2020)$,

$r(x, 2021)$, and $r(x, 2022)$ were inconsistent across different ages, suggesting that

increased mortality among ages older than a^H have clearly contributed to the increase of

$h(t)$ in 2021 and 2022. (Also see Supplementary Figures 7 and 8 for results on female

and male populations)

Discussion

200   Our study showed the pattern of deaths in Japan during the COVID-19

epidemic (up to 2022) through demographic information. The main finding was the

growing impact of the older population and cardiovascular deaths on the shortening of

life expectancy, which was considerable from 2021 to 2022. The lack of significant

correlations between life expectancy change and epidemiological indicators of the

COVID-19 burden from 2022 is also a concern. This finding may be linked to the low

detection of COVID-19 cases and associated deaths, which is supported by our results

about the age- and cause-specific contributions to life expectancy change. The

increasing trend in life span equality despite the life expectancy shortening may also be

related to the substantial increase in mortality among the older population.

There were two key findings from our study. The first was that all age groups

over 30 years old contributed to the shortening of life expectancy in 2022, as shown in

Figure 3 and Supplementary Figure 1. However, compared with the overall shortening

attributed to age groups over 50 in 2021, the negative impact was more diffuse across

ages. This finding is similar to what was observed in 2020–21 in countries in Eastern

Europe, though the underlying situations in these countries, such as types of circulating

SARS-CoV-2 variants, vaccine coverage, and healthcare situations, would have been

quite different from that in Japan from 2021–22. (5) In Japan, the population-wide

vaccine coverage of the second dose of mRNA vaccines (BNT162b2 [Pfizer/BioNTech]

and mRNA-1273 [Moderna] vaccines) was around 80% by the end of 2021, and the

coverage of the third dose also increased from around 15% at the end of 2021 to 68% by

the end of 2022. (33) Despite this high vaccination rate, we found substantial mortality

caused by COVID-19 in Japan among wider age groups in 2022. This was not fully

captured by COVID-19 statistics, as seen in our prefectural analyses (Figure 2 and

Table 1).

Another key finding was the substantial growth in the negative contribution of

cardiovascular disorders to life expectancy shortening, especially among populations

over 50 years old (Figure 3 and Supplementary Figure 2). This was not surprising,

because published studies have shown an elevated risk of cardiovascular diseases

associated with COVID-19. (12–14,34) However, to our knowledge, our study is the

first to have quantified the magnitude of life expectancy shortening in Japan caused by

cardiovascular deaths in 2022. The negative change in contributions by respiratory

causes from 2021 to 2022 and the consistently negative trend in contributions by

neoplastic disorders since 2020 are also of note. In addition to COVID-19-associated

conditions, these findings may be attributable to an array of factors including changes in

hospital attendance. (18) There is a gap between these findings and the global and

regional cause-specific contributions to life expectancy change from 2019–21. (35)

Further update on this issue is warranted to evaluate changes in life expectancy change

by causes of death. The increase in the contribution of remaining causes of death is

mostly explained by the increase in deaths due to senility, which increased by around

20,000 in 2021 and 27,000 in 2022. (25)

241    The changes in life span equality during the COVID-19 pandemic were also of

242 note. Our result highlights the undesirable increase in life span equality despite the

243 shortening of life expectancy at birth. This was in line with the substantial negative

244 contribution by the older population to life expectancy changes in the same period,

245 highlighted by the Arriaga decomposition results. These findings add to demographic

246 case studies on the historical relationship between life expectancy and life span equality.

247 (22,23)

248    Our study had some limitations. First, we could not examine the relationship

249 between COVID-19 and other causes of death in detail at the prefectural level, because

250 data on prefectural death count stratified by age and cause of death are not openly

251 accessible. Detailed analysis of prefectural data would have provided insights on

252 geographic heterogeneity, and we hope to explore this in future. Second, we ignored

253 geographic and temporal variation in the ascertainment bias for COVID-19 statistics.

254 We sufficiently met our key focus to be confident about the true mortality burden of

255 COVID-19, but these factors could have biased our analysis of the relationship between

256 prefectural COVID-19 statistics and life expectancy change. Third, we did not consider

257 the fluctuation in the coverage of death registrations in Japan from 2019–22. However,

258 it is unlikely that we missed a large proportion of deaths that would substantially affect

our results, because the completeness of death registration is reported to be 90–99% in

Japan. (36)

In conclusion, our demographic analysis showed the impact of the COVID-19

epidemic up to 2022, when the epidemic grew substantially larger. The demographic

burden of the pandemic increased more in 2022 than in 2021 or before, but the COVID-

19 burden reported by epidemiological surveillance failed to capture this trend. This is

probably due to both the shrinking coverage of epidemiological surveillance and the

growing impact of COVID-19-associated deaths caused by complications such as

cardiovascular disorders. We also showed an undesirable increase in life span equality

due to disproportionately higher mortality among older people. Our study therefore

provides valuable insights into the mortality impact of the COVID-19 epidemic in Japan,

which can now only be captured by indirect measures such as demographic analysis in

the absence of meticulous epidemiological surveillance.

Acknowledgment

We thank Melissa Leffler, MBA, of Edanz (https://jp.edanz.com/ac) for editing a draft

of this manuscript.

Funding Sources

Y.O. received funding from the SECOM Science and Technology Foundation.

H.N. received funding from Health and Labour Sciences Research Grants [grant

numbers 20CA2024, 21HB1002, 21HA2016, and 23HA2005], the Japan Agency for

Medical Research and Development [grant numbers JP23fk0108612 and

JP23fk0108685], JSPS KAKENHI [grant numbers 21H03198 and 22K19670], the

Environment Research and Technology Development Fund [grant number

JPMEERF20S11804] of the Environmental Restoration and Conservation Agency of

Japan, Kao Health Science Research, the Daikin GAP Fund of Kyoto University, Japan

Science and Technology Agency SICORP program [grant numbers JPMJSC20U3 and

JPMJSC2105], the CREST program [grant number JPMJCR24Q3], and RISTEX

program for Science, Technology, and Innovation Policy [grant number JPMJRS22B4].

The funders had no role in the study design, data collection and analysis, decision to

publish, or preparation of the manuscript.

Conflict of interest

We declare that we have no conflicts of interest.

Ethical approval statement

Ethical approval was not required because all data used in the present study did not

include any personally identifiable information.

Data availability

We used openly accessible COVID-19 statistics from the website of the Ministry of

Health, Labour or Welfare, and life tables and related statistics from the website of

National Institute of Population and Social Security Research. The supplementary files

include the datasets used in this study, and also the results of our numerical analyses.

None of the data used in the present study contained personally identifiable information.

References

1. Bilal U, Hessel P, Perez-Ferrer C, Michael YL, Alfaro T, Tenorio-Mucha J, et al.
Life expectancy and mortality in 363 cities of Latin America. Nat Med. 2021
Mar;27(3):463–70.

2. COVID-19 Excess Mortality Collaborators. Estimating excess mortality due to the
COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-
21. Lancet. 2022 Apr 16;399(10334):1513–36.

3. Msemburi W, Karlinsky A, Knutson V, Aleshin-Guendel S, Chatterji S, Wakefield
J. The WHO estimates of excess mortality associated with the COVID-19
pandemic. Nature. 2023 Jan;613(7942):130–7.

4. GBD 2021 Demographics Collaborators. Global age-sex-specific mortality, life
expectancy, and population estimates in 204 countries and territories and 811
subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a
comprehensive demographic analysis for the Global Burden of Disease Study 2021.
Lancet. 2024 May 18;403(10440):1989–2056.

5. Schöley J, Aburto JM, Kashnitsky I, Kniffka MS, Zhang L, Jaadla H, et al. Life
expectancy changes since COVID-19. Nat Hum Behav. 2022 Dec;6(12):1649–59.

6. Aburto JM, Schöley J, Kashnitsky I, Zhang L, Rahal C, Missov TI, et al.
Quantifying impacts of the COVID-19 pandemic through life-expectancy losses: a
population-level study of 29 countries. Int J Epidemiol. 2022 Feb 18;51(1):63–74.

7. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact
of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet
Infect Dis. 2022 Sep 1;22(9):1293–302.

8. Link-Gelles R, Levy ME, Natarajan K, Reese SE, Naleway AL, Grannis SJ, et al.
Estimation of COVID-19 mRNA vaccine effectiveness and COVID-19 illness and
severity by vaccination status during Omicron BA.4 and BA.5 sublineage periods.
JAMA Netw Open. 2023 Mar 1;6(3):e232598.

9. Rossman H, Meir T, Somer J, Shilo S, Gutman R, Ben Arie A, et al. Hospital load
and increased COVID-19 related mortality in Israel. Nat Commun. 2021 Mar
26;12(1):1904.

10. Hayashi K, Nishiura H. Time-dependent risk of COVID-19 death with
overwhelmed health-care capacity in Japan, 2020-2022. BMC Infect Dis. 2022 Dec
12;22(1):933.

11. French G, Hulse M, Nguyen D, Sobotka K, Webster K, Corman J, et al. Impact of
hospital strain on excess deaths during the COVID-19 pandemic - United States,
July 2020-July 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 19;70(46):1613–
6.

12. Knight R, Walker V, Ip S, Cooper JA, Bolton T, Keene S, et al. Association of
COVID-19 with major arterial and venous thrombotic diseases: A population-wide
cohort study of 48 million adults in England and wales. Circulation. 2022 Sep
20;146(12):892–906.

13. Raisi-Estabragh Z, Cooper J, Salih A, Raman B, Lee AM, Neubauer S, et al.
Cardiovascular disease and mortality sequelae of COVID-19 in the UK Biobank.
Heart. 2022 Dec 22;109(2):119–26.

14. Lee WE, Woo Park S, Weinberger DM, Olson D, Simonsen L, Grenfell BT, et al.
Direct and indirect mortality impacts of the COVID-19 pandemic in the United
States, March 1, 2020 to January 1, 2022. Elife. 2023 Feb 22;12:e77562.

15. Kayano T, Sasanami M, Kobayashi T, Ko YK, Otani K, Suzuki M, et al. Number
of averted COVID-19 cases and deaths attributable to reduced risk in vaccinated
individuals in Japan. Lancet Reg Health West Pac. 2022 Nov;28(100571):100571.

16. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-
19 vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med.
2022 Apr 21;386(16):1532–46.

17. Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J, COVID-19
Genomics UK Consortium, et al. SARS-CoV-2 variant biology: immune escape,
transmission and fitness. Nat Rev Microbiol. 2023 Mar;21(3):162–77.

18. Munira MS, Okada Y, Nishiura H. Life-expectancy changes during the COVID-19
pandemic from 2019-2021: estimates from Japan, a country with low pandemic
impact. PeerJ. 2023 Aug 16;11:e15784.

19. Woolf SH, Masters RK, Aron LY. Effect of the covid-19 pandemic in 2020 on life
expectancy across populations in the USA and other high income countries:
simulations of provisional mortality data. BMJ. 2021 Jun 23;373:n1343.

20. Nomura S, Eguchi A, Tanoue Y, Yoneoka D, Kawashima T, Suzuki M, et al.
Excess deaths from COVID-19 in Japan and 47 prefectures from January through
June 2021. Public Health. 2022 Feb 1;203:15–8.

21. Excess and Exiguous Deaths Dashboard in Japan [Internet]. 2024 [cited 2024 Oct
31]. Excess and Exiguous Deaths Dashboard in Japan. Available from:
https://exdeaths-japan.org/

22. Aburto JM, Villavicencio F, Basellini U, Kjærgaard S, Vaupel JW. Dynamics of
life expectancy and life span equality. Proc Natl Acad Sci U S A. 2020 Mar
10;117(10):5250–9.

23.   Colchero F, Rau R, Jones OR, Barthold JA, Conde DA, Lenart A, et al. The
emergence of longevous populations. Proc Natl Acad Sci U S A. 2016 Nov
29;113(48):E7681–90.

24.   National Institute of Population and Social Security Research. The Japanese
Mortality Database [Internet]. 2023 [cited 2024 Oct 24]. Available from:
https://www.ipss.go.jp/p-toukei/JMD/index-en.asp

25.   Ministry of Health Labour and Welfare. Vital statistics of Japan Final data General
mortality | File | Browse Statistics | Portal Site of Official Statistics of Japan
[Internet]. 2024. Available from: https://www.e-stat.go.jp/en/stat-
search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cy
cle=7&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&
cycle_facet=tclass1&tclass4val=0

26.   Ministry of Health Labour and Welfare. Visualizing the data: information on
COVID-19 infections [Internet]. 2023 [cited 2024 Sep 4]. Available from:
https://covid19.mhlw.go.jp/en/

27.   Arriaga EE. Measuring and explaining the change in life expectancies.
Demography. 1984 Feb;21(1):83–96.

28.   Arriaga EE. Changing Trends in Mortality Decline during the Last Decades. In:
Differential Mortality. 1989. p. 105–29.

29.   Keyfitz N. Mortality Comparisons; The Male-Female Ratio. 1985;54–76.

30.   Aburto JM, Alvarez JA, Villavicencio F, Vaupel JW. The threshold age of the
lifetable entropy. Demogr Res. 2019;41:83–102.

31.   Demetrius L. Demographic Parameters and Natural Selection. Proc Natl Acad Sci
U S A. 1974 Dec 1;71(12):4645–7.

32.   R Core Team. R: The R Project for Statistical Computing [Internet]. 2023.
Available from: https://www.r-project.org/

33.   Cabinet Secretariat of the Japanese Government. COVID-19 Vaccine
informations.(in Japanese) [Internet]. 2024. Available from:
https://www.kantei.go.jp/jp/headline/kansensho/vaccine.html

34. Burn E, Duarte-Salles T, Fernandez-Bertolin S, Reyes C, Kostka K, Delmestri A,
et al. Venous or arterial thrombosis and deaths among COVID-19 cases: a
European network cohort study. Lancet Infect Dis. 2022 Aug 1;22(8):1142–52.

35. Naghavi M, Ong KL, Aali A, Ababneh HS, Abate YH, Abbafati C, et al. Global
burden of 288 causes of death and life expectancy decomposition in 204 countries
and territories and 811 subnational locations, 1990–2021: a systematic analysis for
the Global Burden of Disease Study 2021. Lancet [Internet]. 2024 Apr;0(0).
Available from: http://www.thelancet.com/article/S0140673624003672/fulltext

36. United Nations Statistics Division. Birth and Death Registration Completeness
Last update: April 2023 [Internet]. 2023. Available from:
https://unstats.un.org/unsd/demographic-social/crvs/documents/2023-
completeness.xlsx

Figure 1. Life expectancy changes from 2019-20, 2020-21, and 2021-22 by
prefecture.
Changes from (A) 2019-20, (B) 2020-21, and (C) 2021-22 are shown. In each panel,
bars in blue show positive changes, whereas red bars show negative changes. Order of
prefectures are in an ascending order based on the life expectancy change of 2021-22.
422
Figure 2. Correlation between life expectancy changes and COVID-19 burden
based on official statistics.
Correlation between life expectancy changes and the reported numbers of (A) annual
COVID-19 cases, (B) person-day under intensive care due to COVID-19, and (C)
deaths due to COVID-19 are shown. The variables on the x-axis are log-scaled in all
panels. In each panel, individual prefectures are presented by black triangles
representing 2020-21 data, or red dots representing 2021-22 data, respectively. The
horizontal dashed line corresponds to "no year-on-year life expectancy change".
431
Figure 3. Arriaga decomposition of life expectancy change by major cause of death
and age group, for the entire (total) population of Japan.
Decomposed contribution by age for (A) 2019-20, (B) 2020-21, (C) 2021-22 are shown
in each panel. Bar for each major cause is colored as shown in the panel below the plots.
Bars representing major causes with positive contribution to life expectancy are stacked
on the right-hand side, whereas those with negative contributions are stacked on the
left-hand side.
439
440
441 **Figure 4. The trend of life span equality from 2000 to 2022, for the entire (total)**
442 **population of Japan.**
443 Panel (A) shows the dynamics of life span equality along time from 2000 to 2022. Panel
444 (B) shows the same dynamics in relation to life expectancy for the same period, where
445 the years corresponding to the red dots are noted within the figure.
446
447

448 **Table 1. Life expectancy change and COVID-19 statistics: summary of linear**
449 **regression analysis.**

COVID-19 data (log-scale)	Year	Coefficient (95% CI*)	Intercept (95% CI)
Cases	2020-21	-0.104 (-0.189, -0.018)	-0.655 (-1.086, -0.224)
	2021-22	-0.104 (-0.496, 0.288)	-0.652 (-1.266, -0.037)
Person-days in intensive care	2020-21	-0.082 (-0.144, -0.021)	-0.704 (-1.132, -0.277)
	2021-22	-0.053 (-0.117, 0.011)	-0.879 (-1.353, -0.405)
Death	2020-21	-0.067 (-0.137, -0.002)	-0.789 (-1.464, -0.114)
	2021-22	-0.105 (-0.269, 0.060)	-1.338 (-2.671, -0.057)

451 *CI, confidence interval

Life expectancy changes (years) by prefecture, Total Population

Life expectancy changes (years) and reported COVID-19 burden by prefecture

(A) Trend of h, 2000-22

(B) Life Expectancy at Birth and h, 2000-22